

# Executive Summary

## Mohnark Pharmaceuticals INC

[Mohnark Pharmaceuticals](#) Inc. is a small Veteran-Owned business, headquartered in Fort Pierce. Mohnark Pharmaceuticals specializes in the manufacturing of generic topical pharmaceutical products. Their product line includes OTC and prescription-equivalent gels and creams such as Lidocaine, Diclofenac Sodium, and Adapalene.

Mohnark Pharmaceuticals mission is to provide high quality, affordable topical pharmaceuticals with emphasis on domestic manufacturing and supply chain resilience.



### PROJECT SCOPE

*Business Expansion*



### CAPITAL INVESTMENT

*Facility: \$600,000*

*Equipment: \$1.4 Million*



### JOB CREATION

*New: 11*

*Avg Wage: \$53,664*

*108% SLC 2025 Average*

### NEW JOBS (Recurring Impact)

Impact	Employment	Labor Income	Output
Direct	11.00	\$710,638.68	\$4,636,522.39
Indirect	3.76	\$161,044.36	\$671,324.82
Induced	2.42	\$100,195.92	\$407,946.16
<b>Total</b>	<b>17.18</b>	<b>\$971,878.96</b>	<b>\$5,715,793.37</b>

#### Incentives for consideration:

- Ad Valorem Tax Exemption on TPP (City/County): Years 1-2 80%, Years 3-4 70%, Year 5 - 60%, Year 6 - 40%.
- Job Growth Investment Grant (County): Total of +/- \$18,150 over 2 years
- Expedited Approvals & Permitting

Data is based on 2025 dollars and 2024 IMPLAN data using the category "Pharmaceutical Manufacturing and Admin." Results may vary based on the unique characteristics of each project. The projections in this report are based on IMPLAN data and models, which include certain assumptions and estimates. While we strive for accuracy, these projections are subject to limitations such as data quality, model assumptions, and external factors that may impact results. Therefore, the findings should be interpreted as estimates and not exact figures. Users should consider these results as one of many tools in economic planning and decision-making.